U.S.A. sanction one more embryo's stem cell's clinical trial

U.S.A. sanction one more embryo's stem cell's clinical trial
Xinhua News Agency Washington 11 Cable of the 22nd of moon (reporter Ren HaiJun) American Advanced Cell Technology Inc announces on the 22nd, American Food and Drug Administration has already approved this company for utilizing embryo's stem cell's treatment to treat the clinical trial of the disease of special dose of Sri Lankan. This is that American medicine is in charge of the second human embryo's clinical trial of stem cell's treatment that the office sanctions being implemented.
Sri Lankan special dose disease one hereditary the intersection of eyes and disease, eyesight drop and symmetrical the intersection of macula lutea and the intersection of regression and wither as main characteristic with eyes. Because most patients have illness coming on at 10 years old 20 years old, is known as the juvenile macula lutea to change the sex again. The disease have effective treatment yet at present, Advanced Cell Technology Inc hope, induce, develop into the leather cells at the retinal pigment human the intersection of embryo and stem cell, inject it into patient's eye, thus achieve the goal of treating.
Advanced Cell Technology Inc will recruit in the first batch 12 patients launch the clinical trial . It is pitched that this Robert, chief scientific officer of company, is blue to show, if test clinically the result is good, they will further develop the treatment of degradating to the macula lutea, this will have broader using value. It is reported U.S.A. and Europe have about 3000 people Wan suffer from, may cause blind macula lutea degradate relevant disease alone at present.
Embryo's stem cell can divide into any type of body cells, there is extensive application prospect in medical science. However, because embryo's stem cell should draw from the embryo, involve ethics and ethical question, study relevantly and cause much controversies in U.S.A. . American medicine is in charge of office's approving the outstanding dragon's biological pharmaceuticals for utilizing embryo's stem cell to treat the clinical trial that the spinal damages the patient in October of this year, this is the clinical trial of stem cell's treatment of an embryo that U.S.A. sanctions being implemented.
|